Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

Shandong Cancer Hospital and Institute is the lead sponsor of 33 current clinical trials in our China register. 26 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, Ivonescimab and Sintilimab. The most-studied condition is Radiotherapy.

ClinicalTrials.gov trials by status

Recruiting2679%
Not yet open412%
Active, closed39%

Trials by phase

Phase 21648%
Phase 3618%
Not applicable412%
Observational39%
Phase 1/226%
Phase EARLY_PHASE113%
Phase 413%

Clinical trials sponsored by Shandong Cancer Hospital and Institute

33 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours NCT07808177 · ClinicalTrials.gov ↗ · Fibroblast Activation Protein (FAP)-Positive Advanced Solid Tumours	Phase EARLY_PHASE1	Recruiting	2026-06	China
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma NCT06532539 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis Drugs: Cadonilimab, Paclitaxel and Cisplatin	Phase 2	Recruiting	2024-06	China
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer NCT06942416 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-02	China
The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy NCT07376174 · ClinicalTrials.gov ↗ · Breast Cancer, HER2/CEP17 Ratio	Observational	Recruiting	2026-01	China
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC NCT06841172 · ClinicalTrials.gov ↗ · OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy	Phase 3	Recruiting	2025-07	China
Early Screening Cohort Study of Multiple Gastrointestinal Tumors NCT07106424 · ClinicalTrials.gov ↗ · Early Detection of Cancer	Observational	Recruiting	2024-09	China
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer NCT07686640 · ClinicalTrials.gov ↗ · Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy	Phase 3	Recruiting	2026-08	China
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer NCT06050317 · ClinicalTrials.gov ↗ · Pancreas Cancer Drug: Sintilimab	Phase 2	Recruiting	2023-08	China
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial NCT06850090 · ClinicalTrials.gov ↗ · Rectal Cancer, Rectal Cancer Patients	Phase 3	Recruiting	2025-07	China
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer. NCT06778382 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant	Phase 2	Recruiting	2024-06	China
Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer NCT07408505 · ClinicalTrials.gov ↗ · Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome Drug: Nano-crystalline Megestrol Acetate	Not applicable	Recruiting	2026-06	China
Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury NCT06847555 · ClinicalTrials.gov ↗ · To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients	Phase 1/2	Recruiting	2025-05	China
SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue NCT06987370 · ClinicalTrials.gov ↗ · Bone Metastases in Subjects With Advanced Cancer	Not applicable	Recruiting	2025-06	China
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT) NCT07026422 · ClinicalTrials.gov ↗ · Rectal Malignant Neoplasms	Phase 2	Recruiting	2025-04	China
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807 · ClinicalTrials.gov ↗ · IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma Drug: Camrelizumab	Phase 2	Recruiting	2022-12	China
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer NCT06802757 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Anthracycline, Carboplatin, Cyclophosphamide	Phase 2	Recruiting	2025-05	China
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents NCT06816771 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma, Recurrent, Refractory Drug: Pazopanib	Phase 2	Recruiting	2025-02	China
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer NCT07600268 · ClinicalTrials.gov ↗ · Pancreatic Cancer Non-resectable	Phase 2	Recruiting	2025-08	China
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma NCT07274774 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma	Phase 2	Recruiting	2025-11	China
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy NCT04829708 · ClinicalTrials.gov ↗ · Limited Stage Small Cell Lung Cancer	Phase 3	Recruiting	2021-04	China
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma NCT07333274 · ClinicalTrials.gov ↗ · Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer Drug: Nimotuzumab	Phase 3	Recruiting	2026-01	China
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases NCT06356584 · ClinicalTrials.gov ↗ · Colorectal Cancer, Immunotherapy, Radiotherapy Drug: Fruquintinib	Phase 2	Recruiting	2024-04	China
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma NCT06980259 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS)	Not applicable	Recruiting	2025-05	China
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma NCT05933967 · ClinicalTrials.gov ↗ · The First Affiliated Hospital of Nanchang University Drugs: Orelabrutinib, R-Chop	Phase 2	Recruiting	2023-06	China
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) NCT06844422 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drug: Ivonescimab	Phase 1/2	Recruiting	2025-02	China
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases NCT07062055 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases Drug: Anti-VEGF	Phase 2	Recruiting	2025-07	China
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. NCT06649448 · ClinicalTrials.gov ↗ · Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF Drugs: Carboplatin, Carboplatin/cisplatin-etoposide, Carboplatin/pemetrexed	Not applicable	Not yet open	2024-10	China
Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer NCT07595107 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Not yet open	2026-06	China
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer NCT07683221 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: IBI310, SBRT, Sintilimab	Phase 2	Not yet open	2026-07	China
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer NCT07093931 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Albumin paclitaxel, Carboplatin, Docetaxel	Phase 4	Not yet open	2025-08	China
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer NCT07173387 · Pancreatic Cancer	Phase 2	Active, closed	2025-10	China
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment NCT07669051 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer) Drugs: Egfr-Tki, Ivonescimab	Phase 2	Active, closed	2026-01	China
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer NCT06246344 · ClinicalTrials.gov ↗ · Rectal Cancer Drugs: Capecitabine, Capeox	Phase 3	Active, closed	2023-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shandong Cancer Hospital and Institute trials

32 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Shandong Cancer Hospital and Institute trials

46 conditions

Radiotherapy4 Pancreatic Cancer3 Breast Cancer3 Rectal Cancer3Neoplasm Recurrence, Local2Immunotherapy2 Hepatocellular Carcinoma2Fibroblast Activation Protein (FAP)-Positive Advanced Solid Tumours1Endometrial Neoplasms1 Neoplasm Metastasis1 Cervical Cancer1Oligometastatic1HER2/CEP17 Ratio1OligoProgressive Metastatic Disease1Hepatocellular Carcinoma (HCC)1Systemic Therapy1Early Detection of Cancer1Local Advanced Rectal Cancer1Solid Tumor Cancer1Chemotherapy Induced Neutropenia1G-CSF1Pancreas Cancer1 Rectal Cancer Patients1Colorectal Neoplasms Malignant1

By trial register

Register	Trials	Recruiting
Clinical trials in China	33	26

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Radiotherapy

Sponsor	Trials
Sixth Affiliated Hospital, Sun Yat-sen University	8
Centre Francois Baclesse	3
Centre Leon Berard	2
Hubei Cancer Hospital	2
Fujian Cancer Hospital	2
Tao Zhang	2
Ontario Clinical Oncology Group (OCOG)	2
Chinese Academy of Medical Sciences	1
Chuangzhen Chen	1

Sponsors with the most current trials registered for this condition.

Questions about Shandong Cancer Hospital and Institute trials

How many clinical trials does Shandong Cancer Hospital and Institute sponsor?

Shandong Cancer Hospital and Institute is the lead sponsor of 33 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Shandong Cancer Hospital and Institute trials recruiting?

Yes. 26 of its 33 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shandong Cancer Hospital and Institute testing?

Its current trials name 32 drugs and biologicals as interventions. The most frequent are Carboplatin (3), Ivonescimab (2), Sintilimab (2), Albumin paclitaxel (1) and Anthracycline (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shandong Cancer Hospital and Institute clinical trials